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Abstract
Background: Amyloid-β oligomers (oAβ) are thought to mediate neurotoxicity in Alzheimer’s disease (AD), and
previous studies in AD transgenic mice suggest that calcium dysregulation may contribute to these pathological
effects. Even though AD mouse models remain a valuable resource to investigate amyloid neurotoxicity, the
concomitant presence of soluble Aβ species, fibrillar Aβ, and fragments of amyloid precursor protein (APP)
complicate the interpretation of the phenotypes.
Method: To explore the specific contribution of soluble oligomeric Aβ (oAβ) to calcium dyshomeostasis and
synaptic morphological changes, we acutely exposed the healthy mouse brain, at 3 to 6 months of age, to naturally
occurring soluble oligomers and investigated their effect on calcium levels using in vivo multiphoton imaging.
Results: We observed a dramatic increase in the levels of neuronal resting calcium, which was dependent upon
extracellular calcium influx and activation of NMDA receptors. Ryanodine receptors, previously implicated in AD
models, did not appear to be primarily involved using this experimental setting. We used the high resolution
cortical volumes acquired in-vivo to measure the effect on synaptic densities and observed that, while spine density
remained stable within the first hour of oAβ exposure, a significant decrease in the number of dendritic spines
was observed 24 h post treatment, despite restoration of intraneuronal calcium levels at this time point.
Conclusions: These observations demonstrate a specific effect of oAβ on NMDA-mediated calcium influx, which
triggers synaptic collapse in vivo. Moreover, this work leverages a method to quantitatively measure calcium
concentration at the level of neuronal processes, cell bodies and single synaptic elements repeatedly and thus
can be applicable to testing putative drugs and/or other intervention methodologies.
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Background
Alzheimer’s disease (AD) is a devastating age-related
neurological disorder characterized by the accumulation
of extracellular amyloid β (Aβ) peptides and intraneuronal
neurofibrillary tangles. Fibrillar amyloid plaques constitute
a major diagnostic hallmark of the disease and correlate
with deleterious local effects including gliosis, neuritic
dystrophies and synapse loss [1, 2]. However, accumu-
lating data suggest that small soluble aggregates of Aβ
(oligomers, oAβ) mainly contribute to neuronal toxicity
[3–7], accumulating in the vicinity of senile plaques
and at the synapse [8]. Despite these important find-
ings, no direct evidence has specifically linked the pres-
ence of oligomers in their natural form with neuronal
dysfunction and spine morphological changes in vivo.
While synthetic Aβ peptides have been extensively used
in the past, they showed a relatively weak potency as
compared with “native” oligomers from AD brains in
physiological concentrations. In transgenic mice, the
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concomitant presence of full-length human APP and its
downstream catalytic fragments has prevented us from
specifically addressing oAβ-related neurotoxicity. We
therefore developed an assay to directly examine the con-
sequences of naturally occurring oAβ on the intact mouse
brain using longitudinal multiphoton calcium imaging,
and observed acute changes in calcium homeostasis,
followed by synaptic loss.
The calcium hypothesis of AD argues that Aβ peptides
impact neuronal calcium homeostasis, leading to synaptic
failure, spine loss, neural network disruption and cognitive
deficits [9–11]. Indirect evidence suggests that calcium
alterations may be an early neuropathological change
associated with mild cognitive impairment in AD patients
[12–14]. Aβ-induced stress has been experimentally linked
with abnormal activation of calcium dependent molecular
cascades [5, 15], alteration of long term potentiation [16]
and memory deficits [16, 17]. The development of new
calcium sensors and their combination with in vivo two-
photon imaging has further allowed a direct evaluation of
calcium changes in AD mouse models, demonstrating in
particular a dramatic increase in resting calcium levels in
a subset of neurites surrounding amyloid deposits [18].
Increased proportions of hypoactive and hyperactive
neurons have been reported in transgenic animals, the
latter being found in clusters near amyloid plaques [19].
At the network level, a gradual decline in visual sensory
performances has been observed in APP mice, a
phenomenon correlated with the amyloid load [20–22].
Intriguingly, most of these studies did not detect changes
before amyloid deposition, with only one previous work
reporting hyperactivity associated with synthetically cross-
linked dimers in vivo [6]. Taken together, testing the
hypothesis that physiologically relevant oAβ causes local
neuritic calcium elevation in the intact brain has not been
achieved.
In the present study, we investigated the effect of natur-
ally occurring soluble oAβ on neuronal calcium homeo-
stasis in adult wild type animals. Acute application of oAβ,
prepared from conditioned media isolated from transgenic
primary neurons (TgCM), to the mouse brain surface
dramatically increased neuronal resting calcium levels,
whereas no change could be observed when conditioned
media collected from the wild-type littermates cultures
(WtCM) was used. This effect was abolished after immu-
nodepletion of Aβ, thus specifically linking the presence of
neurotoxic oAβ with intraneuronal calcium dysregulation.
Because MK-801 efficiently blocked oAβ-induced Ca2+ in-
crease, we also concluded that calcium dysregulation was
primarily mediated through NMDA receptors, whereas
antagonists of intracellular calcium channels were inef-
fective. In this regard, the current work addresses a long-
standing controversy about whether oAβ activates the
release of internal calcium stores or opens cell surface
receptors. In addition, while the calcium rise was rapidly
buffered, synapse loss was only detected after 24 h, dem-
onstrating that oAβ-induced functional alterations pre-
cede morphological changes in vivo. Lastly, the approach
used here to repeatedly measure calcium concentrations
in vivo in the different neuronal compartments, including
soma, dendrites and synaptic elements, may find broad
applications to evaluate modulators of oAβ neurotoxicity
and investigate the impact of various soluble neurotoxic
species relevant in other neurodegenerative diseases.
Methods
Animals
Tg2576 males (Taconic Farms), which heterozygously
overexpress human APPswe under the PrP promoter, were
mated with wild-type females (B6;SJL) for preparation of
primary cortical neurons. In vivo imaging experiments were
performed using wild-type C57BL/6 males (3–6 months of
age, Charles River). Each experimental group consisted of 3
to 6 animals.
Preparation of wild type and transgenic neuronal
conditioned media and Aβ immunodepletion
Cortical neurons were prepared as previously described
[15] and plated on 35-mm culture dishes coated with
poly-D-lysine (Sigma-Aldrich) and maintained in Neuro-
basal/B-27 media. Tissue from each embryo was collected
and used for genotyping using PCR. Conditioned media
was collected at 14 days in vitro (DIV) from either
transgenic cultures (TgCM) or their wild-type littermates
(WtCM). The concentrations of Aβ40 and Aβ42 were
quantified by a mouse/human ELISA kit (Wako).
Immunodepletion of human Aβ from TgCM was
performed overnight using the mAb 6E10 (Covance) and
protein G sepharose beads (Sigma-Aldrich). Briefly, to
avoid non-specific binding, protein G beads were washed
with cold Neurobasal medium and incubated with 1 ml of
TgCM for 30 min at 4 °C while shaking. The mixture was
then centrifuged and the beads were discarded. The
supernatant was further incubated with 100 μl pre-washed
protein G beads and 9 μg of 6E10 antibody for 5 h at 4 °C
while shaking. The supernatant was then collected and Aβ
content was measured using a human/mouse ELISA kit
(Wako).
Size exclusion chromatography of condition media
Size exclusion chromatography (SEC) was performed as
previously described [5]. Briefly, TgCM or WtCM was col-
lected from 14 DIV neurons and centrifuged at 3,000 g at
4 °C in Amicon Ultra-15ML 3 K to concentrate proteins
approximately fivefold. Concentrated TgCM or WtCM
was separated by tandem Superdex 75 10/300 GL col-
umns in 50 mM ammonium acetate, pH 8.5, with AKTA
purifier 10 and dialyzed against PBS. Aβ40 content within
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the different fractions was measured after dialysis of the
fractions with PBS using mouse/human ELISA kit (Wako).
Fractions were also subjected to oligomer-specific ELISA
kit (IBL). Assay was performed according to the manufac-
ture instructions.
Viral vector construction and production
The YC3.6 cDNA was cloned into an AAV2 backbone,
under a hybrid cytomegalovirus (CMV) immediate-early
enhancer/chicken β-actin promoter/exon1/intron and be-
fore the woodchuck hepatitis virus posttranscriptional
regulatory element (WPRE). High titers of AAV serotype 8
were produced using the triple transfection protocol by
both the Harvard and UPENN Vector Cores. Viruses were
tittered by quantitative PCR and the final concentrations
of these AAV viral stocks reached 4x1012 vg/ml.
Stereotactic intraparenchymal injection of AAV-CBA-YC3.6
Stereotactic intracortical injections of AAV-CBA-YC3.6
were performed as described previously [23]. Briefly,
animals were anesthetized by intraperitoneal injection of
ketamine/xylazine (100 mg/kg and 50 mg/kg body weight,
respectively) and positioned on a stereotactic frame (Kopf
Instruments). Injections of vector were performed in the
somatosensory cortex with 3 μl of viral suspension using a
33-gauge sharp needle attached to a 10-μl Hamilton
syringe (Hamilton Medical), at a rate of 0.1 μl/min.
Stereotactic coordinates of the injection sites were calcu-
lated from bregma (anteroposterior −1 mm, mediolateral
± 1 mm and dorsoventral − 1 mm).
Cranial window implantation
One month after injection of AAV-CBA-YC3.6, mice were
anesthetized with isoflurane (1–1.5%) and a cranial win-
dow was implanted by removing a piece of skull above the
somatosensory cortex and replacing it with a 8 mm diam-
eter cover glass (as described previously [24]). For all ex-
periments, the dura mater was removed prior to window
installation. Texas Red dextran (70 kDa; 12.5 mg/ml in
PBS; Molecular Probes) was injected into a lateral tail vein
before imaging to provide a fluorescent angiogram. Mice
were imaged first to determine resting calcium at baseline.
The window was then opened and closed again along with
either WtCM, TgCM or depleted-TgCM diluted 1:1 with
PBS (final volume applied was 50 μl). The window, con-
taining the applied solution, was then resealed with dental
cement. One hour later, each animal was reimaged at the
same fields of view to determine the relative changes in
[Ca2+] (ΔR/Ri) i. To test the effect of different calcium
channel inhibitors, both dantrolene (5 μM) and MK-801
(5 μM) were incubated on the brain for 10 min before top-
ical application with TgCM and each inhibitor mixed to-
gether for another hour.
In vitro resting calcium imaging and measurements
To evaluate the effect of calcium channel antagonists in
vitro using Tg2576 primary neurons, we used two
different ratiometric calcium indicators, indo-1 AM (Life
technologies) and YC3.6. For indo 1- experiments, 10–
12 DIV cultures were incubated with 5 μM indo-1 AM
for 45 min before imaging. For YC3.6 experiments, cells
were transfected at 7 DIV with a pAAV-CBA-YC3.6
plasmid, using Lipofectamine 2000 (Life technologies),
and imaged 2–3 days later. In both cases, hAPPsw trans-
genic neurons were imaged before and after bath appli-
cation of an antagonist to calcium channels, using an
LSM510 confocal microscope (Zeiss) with an environ-
mental chamber that maintains constant conditions of
37 °C and 5% CO2. In the case of indo-1, a chameleon
laser (Coherent, Inc) generated two photon excitation at
750 nm and emitted light was collected at 390–465 nm
and 468–533 nm corresponding to the calcium bound
and unbound dye, respectively. For YC3.6 experiments,
single photon excitation was used at 458 nm using an
argon laser, and emitted light was collected using the
435–485 BP and 505 LP filters for detection of CFP and
YFP fluorescence, respectively. We tested the effect of the
following agents on resting calcium levels in transgenic
neurons: NiCl2 (100 μM), nifedipine (5 μM), ω-conotoxin
(1 μM), MK-801 (5 μM), 2-APB (100 μM) and dantrolene
(10 μM). All pharmacological agents were purchased from
Sigma-Aldrich and dissolved either in double distilled
water (ddw) or DMSO according to the manufacturer
instructions. For indo-1 AM experiments, 5–6 fields of
view were imaged randomly before and 10–15 min after
bath application of the inhibitor. During culture experi-
ments with YC3.6, a limited number of neurons were
transfected, allowing us to reimage the same cells before
and after treatment and thus to calculate the relative
change in YFP/CFP ratio for each cell (ΔR/Ri). Each ex-
periment was repeated over 3–4 independent trials.
In vivo multiphoton imaging
For in vivo calcium imaging, an Olympus FluoView
FV1000MPE multiphoton laser-scanning system mounted
on an Olympus BX61WI microscope and an Olympus
25× dipping objective (NA = 1.05) were used. A Deep-
See Mai Tai Ti:sapphire mode-locked laser (Mai Tai;
Spectra-Physics) generated two-photon excitation at
860 nm, and detectors containing three photomultiplier
tubes (Hamamatsu, Ichinocho) collected emitted light
in the range of 460–500, 520–560 and 575–630 nm.
Mice were placed on the microscope stage and heated
using a heating pad with feedback regulation from a
rectal temperature probe (Harvard apparatus). Four to
six cortical volumes (Z-series, 127 μm× 127 μm, 2 μm
slices, depth of 200–300 μm) were taken per mouse, be-
fore and after topical application of conditioned media,
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at a resolution of 512 × 512 pixels. Because of those im-
aging settings (small field of view and slow scan speed)
we mostly did not record any type of neuronal oscillations
(1.66 s per frame > 1Hz). CFP and YFP PMTs settings
remained unchanged throughout the different imaging
sessions. Laser power was adjusted as needed.
Image processing and analysis
Cell cultures
Cells were imaged using a confocal Zeiss LSM510
system. Images were processed and analyzed using
ImageJ software (https://imagej.nih.gov/ij/). For indo-1
experiments, single plane images of channels corre-
sponding to calcium bound and unbound dye were ob-
tained. For each channel, the background, corresponding
to the mode of the image, was subtracted and a median
filter with radius 2 was applied before dividing the
emitted fluorescence intensity of the calcium bound
channel by the unbound dye channel, thus creating a
ratio-image. For YC3.6 experiments, single channels
corresponding to CFP and YFP fluorescence were proc-
essed in the same way described for indo-1, creating a
YFP/CFP ratio image. In both cases, cell bodies were
manually selected using the free hand tool, before and
after application of an antagonist. The selected regions
of interest were then placed on the ratio image and
measured. To convert the measured ratios, either for
indo-1 or YC3.6, into calcium concentrations, calibra-
tion experiments were performed in CHO cells using
each calcium indicator and solutions with either zero
or 39 μM calcium in the presence of ionomycin
(20 μM, Life Technologies). This allowed the determin-
ation of the Rmin and Rmax for each indicator (indo-1:
Rmin = 0.54, Rmax = 3.04, YC3.6: Rmin = 0.19, Rmax =
1.618). Ratios were then converted to actual calcium
concentration using the indo-1 KD (250nM) and the KD
of YC3.6 (278nM) with standard ratiometric equations
[25, 26]:








Sf2 and Sb2 represent the intensities at calcium free
and calcium bound of the denominator (i.e. YFP or
Indo-1 at 400 nm).
Pseudocolored images presented were created in
Matlab based on each indicator ratio, which was then
converted to calcium concentration using the empirical
Rmin and Rmax and assigned to the jet colormap. We
used the ratio values to supply the Hue and Saturation
(color) and the reference image to supply the Value
(intensity).
In vivo
Image stacks were processed in Image J as follows: the
background of CFP and YFP channels, corresponding to
the mode of the deepest slice of the z-stack, was sub-
tracted, and a median filter (radius 2) was applied before
dividing the emitted fluorescence intensity of YFP by
CFP, thus creating a ratio image. Neurites, cell bodies
and dendritic spines were identified and selected using
the YFP images. The YFP/CFP ratio was then measured
for each ROI using the ratio images. YFP/CFP ratios were
converted to [Ca2+] i with standard ratiometric equations
(see above) using the in situ KD and Hill coefficient of
YC3.6 we have previously determined [18]. We established
the dynamic range of the indicator in-vivo, using the same
in vivo experimental settings as all our in vivo experi-
ments. Rmin and Rmax were calculated using the lowest
2.5% of plaque-associated neuritic dystrophies (in AD
transgenic mice) and the upper 2.5% of neurites in a dying
mouse, respectively (Rmin = 0.79, Rmax = 4.5).
Dendritic Spine analysis
2D projections of YFP-filled neurites were obtained in
ImageJ. Dendrites of at least 20 μm long with prominent
dendritic spine protrusions, were considered for analysis.
Spines were selected manually and the relative changes
in spine density were calculated for each neurite as com-
pared with the average spine density before treatment
for each animal. The nature of the treatment was kept
blinded until statistical analyses.
Statistical analyses
To assess whether ΔR/Ri values were different between
the treatment groups in Neurite, Soma and Spines, a lin-
ear mixed effects model was fitted with treatment group
as fixed effect and mouse as random effect. The same
model was used for the analysis of Spine density.
To assess whether there was a difference between be-
fore vs. after CM application measurements in each
group separately, a linear mixed effect model was fitted
for each treatment group predicting the difference
(after-before) with a fixed effect of an intercept only and
a random effect of mouse.
YFP/CFP ratios were pooled and presented in histo-
grams. Histograms for each group before treatment
was fitted with a normal distribution curve using the
Graph Pad curve fitting tool. Fisher exact test was
used for comparison of calcium overload before and
after treatment within each group. For the cell culture
data, one way ANOVA with post hoc Dunn’s multiple
comparison test was used for comparison of ΔR/Ri
for each group and its vehicle treatment group (ddw
or DMSO).
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Results
Acute exposure of naturally occurring oAβ to the healthy
living brain disrupts intraneuronal calcium homeostasis
and synaptic integrity in vivo
Previous works have established that resting calcium
levels and neuronal function are affected in transgenic
mice with plaques, whereas no change was observed
before amyloid deposition in most studies [18–21]. We
have previously observed that TgCM treatment of wild
type cortical neurons in vitro induced AD-like morpho-
logical changes that include calcium dyshomeostasis,
calcineurin activation [15], dendritic spine loss and neur-
itic simplification [5].
To appreciate the specific contribution of soluble
oAβ species to calcium dysregulation, we designed an
acute in vivo assay of Aβ neurotoxicity by topically ap-
plying oAβ-enriched medium on the cortical surface of
wild-type C57BL/6 mice. Culture medium from pri-
mary cortical neurons derived from Tg2576 embryos
was used as a source of soluble oAβ (termed TgCM),
which mainly contains low molecular weight oligomers
(dimers to tetramers) as evidence from size exclusion
chromatography (SEC) followed by Aβ40 ELISA (Add-
itional file 1: Figure S1) [5, 15, 27]. To validate the pres-
ence of oAβ in the TgCM, the different SEC fractions
were also subjected to oligomeric Aβ ELISA (IBL) that
utilizes the same antibody for capture and detection.
Additional file 1: Figure S1B shows the presence of oAβ
(at much lower levels compared to total Aβ40 signal) in
both the high and low molecular weight fractions. Higher
levels were detected between fractions 11 and 16, which
corresponds to 13.7 kDa and smaller, very low levels were
detected at fractions 25–28, which correspond to 6.5 kDa
and lower. However, the signal at these fractions was very
close to the limit of the ELISA kit sensitivity. This data
suggest that that most Aβ oligomers within the TgCM are
of low molecular weight.
Conditioned media from non-Tg neurons (termed
WtCM) and Aβ immunodepleted TgCM were used as
controls. Within different batches of TgCM, Aβ40 and
Aβ42 concentration respectively reached 4-8nM and
130–260pM, which corresponds to the levels detected
in human cerebral spinal fluid [28]. Additionally, the
concentration of oAβ in the TgCM reached 400pM to
600pM, representing 7.5–10% of the total amount of
Aβ40. The content of murine Aβ40 in several batches of
WtCM ranged from 200pM to 500pM while murine
Aβ42 could not be detected.
To quantify absolute calcium levels in the brain, mice
were injected with an AAV8 encoding the ratiometric cal-
cium indicator yellow-cameleon YC3.6 [29]. Four weeks
later, a craniotomy was performed above the somatosen-
sory cortex and CFP and YFP fluorescent signals were
measured. After evaluating the baseline neuronal resting
calcium, the cranial window was reopened and either
TgCM or WtCM, diluted 1:1 in PBS (final concentration
of Aβ40 of 2nM in TgCM and 180pM in WtCM), was
directly applied to the brain surface. Using the labeled
brain vasculature as a guide, we were able to reimage the
same field of view and calculate the relative changes in
intracellular calcium. We imaged the first 300 μm of the
cortical surface, which consist of neurites and cell bodies
located in layers II/III (Figs. 1a and 2a).
Using the YC3.6 KD (278nM) previously calculated in
cultures [18] and the dynamic range of the indicator
(Rmin and Rmax) obtained from the in-vivo data ac-
quired using the same microscope under the same set-
tings (see Methods), we converted YFP/CFP ratios into
absolute calcium concentrations. Our measurements
indicate that [Ca2+] i is tightly regulated in wild type
mice and reaches 70 ± 4nM on average. The values of
[Ca2+] i in neurites in wild type brain generally follow a
normal distribution (Fig. 1c, r2 = 0.99). As expected,
only rare neurites would be classified as having calcium
overload at baseline (threshold defined as [Ca2+] i
greater than two SD above the mean of all neurites in
the first imaging session, 90nM). Topical application of
TgCM to the healthy brain progressively increased the
YFP/CFP ratios and thus [Ca2+] i, which reached a peak
after an hour before returning to baseline levels by 5 h
(Additional file 2: Figure S2). One-hour exposure with
TgCM induced a dramatic elevation of intraneuronal
calcium, as evident in the pseudocolored images and the
right shift of the calcium distribution curves towards
higher YFP/CFP ratio values (Fig. 1b, c). TgCM incubation
resulted in a greater number of calcium-overloaded neur-
ites (threshold for calcium overload is represented by a
black line; n = 295 neurites in 5 mice, calcium overload:
before = 3.09%, after = 25.82%, p < 0.0001 Fisher exact
test). Conversely, when mice were incubated with WtCM,
no significant change in calcium levels was observed
(n = 409 neurites in 5 mice, calcium overload: before =
3.8%, after = 1.38%, p = 0.643 Fisher exact test). To
demonstrate that TgCM-induced elevation of [Ca2+] I
was directly related to the presence of Aβ peptides in the
medium, we immunodepleted human Aβ from the TgCM
and followed the same experimental settings. Immunode-
pletion of Aβ with 6E10 antibody effectively removed
about 80% of Aβ present in TgCM (initial concentration
of Aβ40 in TgCM: 4.1nM, after immunodepletion:
0.8nM). The effect of TgCM was abolished after immuno-
depletion and only a modest non-significant trend of
calcium overload was detected (n = 206 neurites in 3 mice,
calcium overload: before = 1.9%, after = 5.8%, p = 0.07
Fisher exact test, comparison of before and after YFP/CFP
ratios p < 0.2847).
Comparing resting calcium before and after treatment
within the same neuronal processes, we observed that
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Fig. 1 Oligomeric Aβ induces calcium overload in the healthy mouse brain. a A new experimental setting was designed to specifically address
the effect of oAβ on calcium homeostasis in vivo. Wild-type C57BL/6 mice were injected with an AAV-CBA-YC3.6 and a cranial window was
installed 4 weeks later. After a first imaging session at baseline, the window was opened and WtCM, TgCM or depleted TgCM was topically
applied for 1 hour before reimaging again the exact same fields of view. b Neurites, consisting of dendrites and axons, filled with YC3.6 were
imaged before and after treatment with TgCM, WtCM or depleted-TgCM. Images were pseudocolored according to calcium concentration (Scale
bar = 20 μm). c Individual neurites were selected for measuring YFP and CFP ratio and calculating resting calcium levels. Distribution curves of
[Ca2+] i (YFP/CFP ratio on the lower x-axis and [Ca
2+] i on the upper x-axis) are presented before (purple curve) and after treatment (red curve) for
each experimental group. Acute exposure to TgCM, but not to WtCM or immunodepleted-TgCM, resulted in a shift in the [Ca2+] i distribution
towards higher ratio values, i.e. higher calcium concentrations. The black line indicates the threshold for calcium overload which represents 2 SD
above the mean of ratios measured from all mice before treatment. The percentage of neurites with calcium overload before (purple) and after (red)
treatment is noted on the graphs. Calcium overload was only significantly increased in the TgCM treated group from 3.09 to 25.82% (p < 0.0001 Fisher
exact test). d YFP/CFP ratios before and after treatment with WtCM, TgCM or depleted TgCM represented for each neurite. The red traces account for
the neurites that showed an increase of ≥10% in YFP/CFP ratio after topical application of CM. e The relative change in ratio was calculated for each
neurite and the mean + SEM of each group is presented (linear mixed effects model fitted with treatment group as fixed effect and mouse as random
effect ** p = 0.0012, *p = 0.0183)
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the YFP/CFP ratios were increased by 10% or more for
the vast majority of TgCM-treated neurites, whereas
such a change was only occasionally observed after
WtCM and depleted-TgCM incubation (Fig. 1d). From
these values we calculated the relative change in YFP/
CFP ratio for each neurite (ΔR/Ri, Fig. 1e) and showed
that TgCM induced an average increase in the YFP/CFP
ratio of 8.5 ± 1.6% (from 70nM to about 85nM). Applica-
tion of TgCM was significantly different from that of
WtCM and depleted-TgCM while the later two groups
were not different from each other (Fig. 1e, linear mixed
effect model. Overall change between the groups p =
0.0029, post hoc comparisons between every 2 groups: p
= 0.0012 TgCM vs. WtCM; p = 0.0183 TgCM vs. de-
pleted TgCM; p = 0.6507 WtCM vs. depleted-TgCM. n =
295 neurites within 5 mice for TgCM, 405 neurites
within 5 mice for WtCM and 206 neurites picked from
3 mice for depleted-TgCM).
When only the overloaded neurites after TgCM treat-
ment were analyzed, the average reached a mean change
of 16.9 ± 4.8% (from 70nM to 100nM). Reimaging the
same fields and analyzing the YFP/CFP ratios in the same
neurites 5 h post treatment did not show any change from
baseline (Additional file 2: Figure S2), suggesting that
elevation in [Ca2+] i was a transient event rapidly buffered
in the healthy brain of wild type mice.
When cell bodies were selected (Fig. 2a and b), resting
calcium concentration at baseline was lower than the level
measured in neurites, averaging at 58nM. Exposure with
oligomeric Aβ also disrupted calcium homeostasis in the
neuronal soma as compared with WtCM treatment
(ΔR/Ri : TgCM 14.4 ± 4.25%, WtCM 2.09 ± 4.2%, pair-
wise comparison, p = 0.0458). However, we could not
analyze the depleted –TgCM as we could trace cell bodies
only in one of 3 mice tested. TgCM treatment effect was
significantly different from that of WtCM.
Fig. 2 Oligomeric Aβ induces calcium overload in neuronal cell bodies and dendritic spines. Neuronal cell bodies (a,b) or dendritic spines (c,d)
were imaged before and 1 h after treatment with conditioned media, and the YFP/CFP ratio and resting calcium were calculated for each
compartment. Images were pseudocolored according to calcium concentrations. b In cell bodies, TgCM, but not WtCM, induced an increase in
resting calcium. (TgCM: n = 165 cells, WtCM: n = 157 cells, in 5 mice, pair-wise comparison of the relative change in YC ratio, * p = 0.0458). d TgCM
effect on YC ratio in dendritic spines followed the same trend as neurites and was significantly different from that of WtCM and depleted-TgCM
(pair-wise analysis TgCM vs. WtCM * p = 0.0466; TgCM vs. depleted-TgCM * p = 0.0494; WtCM vs. depleted-TgCM p = 0.9916). Scale bars = 20 μm in
(a) and 5 μm in (c)
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Dendritic spines showed indistinguishable [Ca2+] i
from that of the neurites (Fig. 2c, d; YFP/CFP ratios
corresponding to about 72 ± 10nM and 70 ± 4nM in
spines and neurites, respectively). Similarly to our ob-
servations in neurites, TgCM application led to a 9.6%
± 2.3% increase in calcium levels (comparison before
and after TgCM: p = 0.0268). WtCM and depleted-
TgCM application did not have any effect (before vs.
after comparison; WtCM: p = 0.3736, depleted-TgCM:
p = 0.5552). The effect of TgCM on the relative change
in calcium was significantly different from that of
WtCM and depleted TgCM, which did not differ from
each others (pair-wise comparisons; TgCM vs. WtCM
p = 0.0466, TgCM vs. depleted TgCM p = 0.0494, WtCM
vs. depleted TgCM p = 0.9916). In contrast with the
acute and dramatic impact of oAβ on intraneuronal cal-
cium, no change in spine density was detected 1 h after
treatment with TgCM (relative change compared with
the average spine density before treatment: −0.2% ±
4.1%, p = 0.9502, 760 spines counted in 4 mice) or with
WtCM (relative change compared with the average
spine density before treatment: 2.2% ± 5.3%, p = 0.708
578 spines counted within 3 mice, Fig. 3). However, a
robust decrease in the density of dendritic spines was
observed 24 h after TgCM application (relative change
compared with the average spine density before treat-
ment: −28.7% ± 4.3%, p < 0.0001, n = 635 spines within 3
mice, Fig. 3), at a time when the calcium levels were
restored to baseline (Additional file 2: Figure S2). By
contrast, non-significant change in spine density was
observed 24 h post application of WtCM (relative
change compared with the average spine density before
treatment (8.9% ± 4%, p = 0.0555, 1382 spines counted
within 3 mice, Fig. 3), suggesting that this observation
did not derive from the surgical procedure itself. Pair-
wise analysis between the two groups (TgCM/WtCM)
showed no difference at 1 h (p = 0.7463) and significant
change in spine density at 24 h (p < 0.0001) after
treatment.
NMDA receptors mediate oAβ-induced increase in resting
calcium
Intracellular changes in neuronal [Ca2+] i can result
from increased entry of extracellular calcium, leakage
of intracellular calcium stores or loss of buffering cap-
acity. To determine the molecular mechanisms under-
lying TgCM-induced calcium dysregulation, we examined
these possibilities in vitro and in vivo.
As a preliminary approach, we used cortical primary
neurons cultured from Tg2576 embryos to perform an
initial screen of various calcium channel inhibitors.
These neurons chronically secrete human Aβ that
oligomerize to form predominantly species from dimers
to tetramers after 14DIV (Additional file 1: Figure S1).
We have previously demonstrated that, similarly to wild
type neurons treated with TgCM, Tg2576 neurons also
exhibit spine loss and decreased neurite arborization
[5, 15]. We assessed the calcium levels with two differ-
ent calcium probes: YC3.6 and the small molecule
ratiometric indicator indo-1/AM. To explore the contri-
bution of the extracellular calcium pool and the role of
voltage gated calcium channels (VGCC), we incubated the
cells with indo-1 AM and imaged before and 10 min after
exposure to 0.5 mM NiCl2. Transgenic neurons in culture
presented a wide distribution of calcium concentrations
(Fig. 4a, note the right tail of the distribution curve).
Before treatment, 21.3% of transgenic neurons showed
Fig. 3 Oligomeric Aβ decreases spine density at 24 h. a Representative
images of YFP-filled neurites and dendritic spines before and after 1 h
or 24 h treatment with WtCM, TgCM and TgCM+MK-801 (Scale bar =
10 μm). b Box plots showing the relative changes in percentage of
spine densities after treatment accordingly to the mean spine density
calculated for each animal before treatment. Whiskers represent the
minimal and maximal values of each experimental group (n = 3–4 mice
per group. For WtCM: n = 58 neurites and 578 spines evaluated after
1 h and n = 91 neurites and 1382 spines evaluated after 24 h. For
TgCM: n = 68 neurites and 760 spines evaluated after 1 h and n = 69
neurites and 635 spines evaluated after 24 h. For TgCM+Mk-801: n =
152 neurites and 854 spines evaluated after 1 h and n = 174 neurites
and 1044 spines evaluated after 24 h. Linear mixed effects model
was fitted with treatment group and time of imaging (as outlined
in the graph) as fixed effect and mouse as random effect. (pair-wise
comparisons: TgCM 1 h vs. 24 h: *** p < 0.0001, Wtcm 1 h vs.
24 h p = 0.3897, TgCM +MK-801 1 h vs. 24 h p = 0.6667)
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calcium overload (marked by a black line, R = 1.32,
467nM), similar to our previous in vivo observations using
this APP mouse model [18]. A 10-min incubation with
NiCl2 significantly decreased the resting calcium levels
and reduced the percentage of calcium overloaded cells
from 21.3% to 9.9% (Tg before: n = 366 neurons in 3 ex-
periments. Tg after NiCl2: n = 321 neurons in 3 experi-
ments, p < 0.0001, Fisher exact test). We then performed
similar experiments with specific pharmacological
blockers of several calcium channels (nifedipine for L-type
VGCC, ω-conotoxin for N-type VGCC and MK-801 for
NMDA-R), as well as inhibitors of intracellular calcium
release from the ER (2-APB for IP3 receptors and dantro-
lene for ryanodine receptors). These experiments were
performed in transgenic neurons transfected with YC3.6
and the sparse expression of YC3.6 allowed us to re-visit
each cell after application and thus appreciate the relative
change in ratio for each neuron (ΔR/Ri). As evident in
Fig. 4c, vehicles alone (water or DMSO) did not affect the
resting calcium in cells. We observed that N-type, L-type
VGCC and NMDA receptor antagonist were effective in
reducing [Ca2+] i in the presence of oAβ by 4.7%, 10.05%
and 19.31%, respectively (One way ANOVA with post hoc
Dunn’s multiple comparison test for comparison across all
groups: Nifedipine vs. DMSO: p < 0.05, ω-conotoxin vs.
ddw: p < 0.0001, MK-801 vs. ddw: p < 0.0001). MK-801 led
to the most dramatic effect (Fig. 4b, c), shifting the distri-
bution curve to the left and reducing calcium overload
from 15.7 to 0.52% (p < 0.0001 Fisher exact test). Dantro-
lene and 2-APB, ryanodine and IP3 receptors antagonists
Fig. 4 Extracellular calcium is the source of calcium overload in primary neurons expressing human APP. a Tg2576 neurons were incubated with
the ratiometric calcium indicator indo-1 AM and then imaged before and after application of NiCl2 to block all voltage gate calcium channels.
The ratios of bound vs. unbound indo-1 were calculated, converted to calcium concentration and pseudocolored using the jet color map. Distribution
curves of [Ca2+] i (bound/unbound ratio on the lower x-axis and [Ca
2+] i on the upper x-axis) are presented in the lower panel showing a wider
distribution at baseline, which became more narrow and was shifted to the left after application of NiCl2. The black line indicates the threshold for
calcium overload. The percentage of neurons with calcium overload, noted on the graphs before and after treatment, is significantly reduced by NiCl2
from 21.3 to 9.9% (n = 366 neurons before treatment and 321 after treatment in three separate experiments, Fisher exact test, p < 0.0001). b Neurons
were transfected with YC3.6 and imaged before and after application of the NMDA receptor antagonist, MK-801. Ratios were converted to calcium
levels and pseudocolored as in A. Upper panel shows resting calcium measured in the same neuron before and after inhibition of NMDA receptors.
Distribution curves of [Ca2+] i (YFP/CFP on the lower x-axis and [Ca
2+] i on the upper x-axis) are shown on the lower panel. Again, the wide distribution
of calcium initially observed in transgenic neurons was shifted to the left after treatment with MK-801, dramatically reducing calcium overload from
15.7 to 0.5% (n = 189 neurons in 4 separate experiments, Fisher exact test p < 0.0001). c Summary bar graph for experiments with antagonists for
different calcium channel measured with YC3.6 as described in B. The relative change in ratio (ΔR/Ri) after exposure with each inhibitor was calculated
for individual cells and presented here as the group mean + SEM (each inhibitor was tested in three independent experiments: vehicles: ddw – n= 243,
DMSO – n= 161; inhibitors: Nifedipine (L-type voltage channels) – n= 158, ω-conotoxin (N-type channels) – n= 141, 2-APB (IP3R) – 173, dantrolene (RyR) –
208). The effect of the treatment was tested by comparing each inhibitor to its appropriate vehicle using one way ANOVA with post hoc Dunn’s Multiple
comparison test (* p< 0.05, ** p< 0.01, ***p< 0.0001). (Scale bar = 50 μm)
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that block calcium release from the ER, did not alter
the resting calcium levels of Tg primary neurons. The
moderate decrease in [Ca2+] i observed when nifedipine
or ω-conotoxin along with the more dramatic effect of
MK-801 strongly support a major role for extracellular
calcium as the source for calcium overload.
To test if oAβ-induced calcium dysregulation also relies
on extracellular stores and NMDAR activation in vivo,
MK-801 (5 μM) was applied on the surface of the brain
for 10 min before and along with the application of TgCM.
As shown in Fig. 5, TgCM failed to affect resting calcium
in mice pretreated with MK-801 (ΔR/Ri comparing before
and after MK-801 + TgCM treatment: p = 0.7719). The
percentage of calcium overloaded neurites also remained
unchanged after MK-801/TgCM application (1.67 to
3.5%, n = 656 neurites from 7 mice, p = 0.0548 Fisher
exact test), while TgCM alone resulted in 25.8% of
neurites showing calcium overload (p < 0.0001, Fisher
exact test). Additionally, we did not see any significant
spine loss 1 h or 24 h after topical application of MK-
801/TgCM (relative change compared with the average
spine density before treatment: at 1 h: 0.4% ± 3.3%, p =
0.9123, and at 24 h: 2.4% ± 3.3; n = 4 mice), implying that
the presence of MK-801 also counteracted the deleterious
impact of oligomeric Aβ species on synapse loss previ-
ously observed with TgCM alone at 24 h. Importantly,
MK-801 alone did not significantly changed calcium over-
load (2.79% to 2.4% overload before and after, p = 0.37,
fisher exact test, n = 322 neurites in 3 mice Fig. 5e), thus
demonstrating that the impact of this inhibitor was
directly associated with oAβ-dependent activation of
NMDAR in the first place. In contrast, treatment with
dantrolene (5 μM) did not counteract the effect of TgCM
(ΔR/Ri comparing before and after dntrolene + TgCM
treatment: p = 0.0003).As evident by the change in the
shape of the neurite distribution curve and the increased
percentage of calcium overloaded neurites (from 2.07 to
21.23%; n = 674 neurites from 4 mice, p < 0.0001 Fisher
Fig. 5 Oligomeric Aβ induces calcium overload through activation of NMDA receptors in vivo. The antagonists MK-801 and Dantrolene were
applied 10-min before and during TgCM application. Distribution curves of [Ca2+] i (YFP/CFP ratio on the lower x-axis and [Ca
2+] i on the upper
x-axis) are presented before (purple curve) and after treatment (red curve) for mice treated with WtCM (a) TgCM (b) MK-801 + TgCM (c), dantrolene +
TgCM (d) and MK-801 alone (e). The black line indicates the threshold for calcium overload. The percent of overloaded neurites is noted on each
graph. Treatment with MK-801, but not of dantrolene, abolished the effect of TgCM on resting calcium (pair-wise comparisons of the relative change
in YC ratio: TgCM vs. TgCM+MK-801 p = 0.0221; TgCM vs. TgCM+Dantrolene p = 0.7656; TgCM +MK-801 vs. TgCM+Dantrolene p = 0.0077)
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exact). To conclude, MK-801 and dantrolene led to an
opposite effect on resting calcium once applied to the
brain along with TgCM (pair-wise comparison TgCM+
MK-801 vs. TgCM+ dantrolene: p = 0.0077), suggesting
that extracellular soluble amyloid species initially act
through activation of these calcium channels in vivo, while
the calcium retained in the ER does not seem to play a
primary role.
Discussion
Disruption of intracellular calcium balance has been
invoked as a potential mechanism of physiological and
pathophysiological changes associated with normal aging
[30] and, to a greater extent, with a variety of neurologic
disorders including schizophrenia [31], bipolar disorder
[32], autism spectrum disorder [33], Parkinson’s disease
[34, 35], Huntington disease [36] and AD [10, 11, 37–39].
The relationship between the pathological hallmarks of
AD and abnormal calcium homeostasis has been a focus
of investigation, and while neurofibrillary tangles seemed
to affect neither resting [Ca2+] i [40] nor neuronal re-
sponses to stimuli [41], the amyloid pathology has been
linked to increased resting calcium [18], neuronal hyper-
activity [19] and a gradual decline in neuronal perform-
ance in response to visual stimuli [20, 21].
Accumulating evidence suggests that soluble oAβ are
more potent neurotoxic species than Aβ fibrils, leading to
synaptic and neural network dysfunction [3, 4, 42–44].
Though the effect of different species of oAβ has been
tested in culture models, studying their relevance in vivo
has been challenging because of the concomitant presence
of amyloid plaques [8, 45]. In this study, we specifically
investigated the effect of naturally secreted soluble species
of Aβ, primarily oAβ, on calcium homeostasis in the
healthy living brain. We utilized conditioned media col-
lected from APP transgenic cortical neurons as the source
of oligomeric Aβ. Unlike synthetic Aβ, which generates
oligomers and fibrils within minutes to hours, naturally
secreted Aβ peptides mainly assemble into low molecular
weight species from dimers to tetramers. We demon-
strated that, when oAβ was acutely applied to the cortical
surface of the healthy mouse brain after cranial window
implantation, the resting calcium levels were dramatically
increased in all cellular compartments including neuronal
soma, processes and dendritic spines. While it is conceiv-
able that the surgical procedure itself sensitizes neurons
towards Aβ neurotoxicity, the calcium rise could not be
attributed solely to the experimental approach itself. In-
deed, removal of Aβ from the conditioned media or, alter-
natively, acute application of conditioned media from wild
type neurons, abolished this effect. Aβ-induced elevation
of resting calcium was significant 1 h after application but
could no longer be detected in the same brains after 5 h,
suggesting clearance of the peptide assemblies, and/or
recovery via intracellular buffering mechanisms. Interest-
ingly, the relatively fast increase of intraneuronal calcium
levels after exposure to Aβ leads to long-lasting morpho-
logical alterations with a significantly decreased spine
density detected only 24 h after treatment with TgCM
while no change could be detected at 1 h. The extent of
oAβ-induced spine loss is similar to what has been re-
ported in the immediate vicinity of amyloid plaques,
where high concentrations of oAβ are thought to exist [8,
45]. The difference in kinetics between oAβ-dependent
calcium overload and synaptic collapse strongly argues in
favor of a primary neuronal dysfunction that precedes
morphological changes at the synapse, perhaps via activa-
tion of calcineurin or other calcium dependent signaling
pathways [5, 15, 27]. This is of particular interest consider-
ing that spine loss is the parameter that correlates best
with cognitive impairment in AD patients [46, 47].
Understanding the source of the calcium entry in the
presence of oAβ and the channels involved is important
as calcium influx through different channels may trigger
various signaling cascades which independently impact
gene transcription and neuronal homeostasis [48]. The
role of extracellular calcium and its influx through the
activation of NMDA receptors was demonstrated in vivo,
as oAβ-dependent calcium rise was prevented by incuba-
tion with MK-801. Indeed, Aβ has been shown to reduce
long term potentiation (LTP) and facilitate long term de-
pression (LTD), processes that involved trafficking of glu-
tamate receptors [49, 50]. In addition, prefibrillar amyloid
and Aβ oligomers have been shown to directly interact
with glutamatergic receptors, activate NMDAR and result
in calcium increase in primary neurons [51–53]. While
those in vitro studies have established a direct association
between oAβ and NMDAR, our results do not exclude the
possibility that intermediate steps also participate in the
rise of intraneuronal calcium levels. For example, patho-
logically elevated levels of Aβ have been shown to block
glutamate uptake at the synaptic cleft, leading to increased
glutamate levels, which could also activate synaptic
NMDA receptors [54]. Whether or not the activation of
NMDAR is a direct or indirect effect of extracellular oAβ,
our data strongly suggest that the rise in intracellular
calcium via NMDAR may impair synaptic plasticity and
spine density, and thus represent the initial steps in the
pathological changes that occur in AD.
ER calcium stores have been suggested to play a role in
regulation of Aβ production [55, 56] and calcium release
from the ER via ryanodine and IP3 receptors has also been
implicated in calcium dyshomeostasis in AD [11, 57, 58].
Specifically, chronic treatment with the ryanodine recep-
tor antagonist, dantrolene, was shown to normalize ER
calcium responses, improve cognitive deficits and modu-
late the amyloid pathology in mouse models of AD [59].
Conversely, our data suggest that oAβ initially facilitates
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calcium entry from extracellular pools, at least largely via
NMDA receptors, whereas ryanodine receptors do not ap-
pear to play a role primarily. It is possible that the ER
pools are involved in a second step in calcium-dependent
calcium release from the ER, resulting in further rise in
cytosolic calcium levels. In the brains of AD mouse
models chronically exposed to Aβ oligomers and fibrils,
the sustained increase in resting calcium [18] may result
from a concomitant dysregulation of extracellular calcium
entry or intracellular calcium buffering systems that fur-
ther induce downstream events such as synapse loss and
alterations in APP processing. This may not be the case in
the healthy brain in which calcium is highly regulated,
explaining why the effect of oAβ on [Ca2+] i is not abol-
ished by blocking RyR, as the initial rise in calcium is not
dependent on ER stores.
Finally, we cannot exclude that exposure of the cortical
surface to oAβ impacts intraneuronal calcium homeosta-
sis via non-cell autonomous mechanisms, eventually in-
volving the participation of astroglial cells as well [60].
The effect of oAβ on cultured astrocytes has indeed been
investigated over the past [61, 62], showing in particular
that oligomerized Aβ can induce astrocytic glutamate re-
lease in an α7nAChR-dependent manner, activate extrasy-
naptic NMDAR and lead to synaptic loss. In vivo studies
in AD mice have revealed that calcium transients in astro-
cytes were more frequent and synchronously coordinated
in transgenic animals as compared with controls [63, 64],
an effect potentially mediated by paracrine purinergic sig-
naling that could be blocked by P2Y receptors inhibitors
[65]. However, most of the work conducted in animals has
been done using transgenic mouse models, so the sole ef-
fect of oAβ on astrocytic calcium homeostasis remains to
be elucidated. Additionally, studying the respective impact
of oligomeric amyloid species concomitantly on neurons
and astrocytes will give further information about the ini-
tial molecular mechanisms in play.
In light of these observations, it is clear that thera-
peutic strategies aimed at reducing or inhibiting
calcium influx into cells through NMDAR may be of
importance. In parallel, efforts to prevent or reduce
the levels of soluble oAβ levels will likely lead to treat-
ments that effectively delay or restore neuronal dys-
function in AD.
Conclusions
The present study demonstrates that low-molecular
weight species of Amyloid β can acutely disrupt neuronal
calcium homeostasis in non-transgenic animals through
the activation of NMDA receptors. Interestingly, although
calcium levels are rapidly restored to baseline, decreased
spine density is detected 24 h after exposure to oAβ,
suggesting that calcium dyshomeostasis precedes synaptic
morphological changes. This work implicates small oAβ
species in the deleterious effects that occur during degen-
erative processes at the synapse.
Additional files
Additional file 1: Figure S1. Biochemical characterization of Aβ
oligomers present in Tg conditioned media (TgCM). a Representative
profile showing the amount of Aβ40 detected by ELISA in each fraction
after separation of the different oligomeric species present in TgCM (red
bars) by size-exclusion chromatography (SEC, Superdex 75 SEC columns).
The molecular weight markers (kDa) that ran at the same conditions are
indicated above (arrowheads). b Measurements of oligomeric Aβ within
each SEC fraction show that most of oAβ is of low molecular weight
(fractions 12–18).. A smaller peak of high-molecular weight species was
also detected in TgCM (fractions 2–6 in both ELISAs). (TIF 1492 kb)
Additional file 2: Figure S2. Time course of oAβ-induced increase in
resting calcium levels after acute exposure with TgCM on a healthy brain.
C57BL/6 mice were injected with AAV-CBA-YC3.6 into the somatosensory
cortex and acutely exposed to TgCM containing oAβ. The changes in
YFP/CFP ratios in the neurites were measured at baseline before treatment
and 30 min, 1 h and 5 h after topical application of TgCM. A progressive
increase in the levels of resting calcium (YFP/CFP ratio and the actual
calcium levels on the lower and upper x-axis, respectively) was detected
that reached a peak after 1 h (20.6% of overloaded neurites), before
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